Hot Features
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-1... Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 1480 | 0.0001 | CS |
| 4 | 0 | 0 | 0.0001 | 0.0003 | 0.0001 | 2493 | 0.00014472 | CS |
| 12 | 0 | 0 | 0.0001 | 0.01 | 0.0001 | 2334 | 0.00012066 | CS |
| 26 | 9.0E-5 | 900 | 1.0E-5 | 0.19 | 1.0E-6 | 28219 | 8.403E-5 | CS |
| 52 | 0 | 0 | 0.0001 | 0.35 | 1.0E-6 | 21068 | 0.00038332 | CS |
| 156 | 9.9E-5 | 9900 | 1.0E-6 | 0.35 | 1.0E-6 | 10176 | 0.0003407 | CS |
| 260 | -0.0018 | -94.7368421053 | 0.0019 | 0.35 | 1.0E-6 | 82787 | 0.06058153 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.